| Combination of | |
|---|---|
| Meloxicam | Nonsteroidal anti-inflammatory drug |
| Rizatriptan | serotonin (5-HT) 1B/1D receptor agonist (triptan) |
| Clinical data | |
| Trade names | Symbravo |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a625033 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Meloxicam/rizatriptan, sold under the brand nameSymbravo, is afixed-dose combination medication used for the treatment ofmigraine.[1] It is a combination ofmeloxicam, anonsteroidal anti-inflammatory medication; andrizatriptan (as rizatriptan benzoate), a serotonin (5-HT) 1B/1D receptor agonist (triptan).[1] It is takenby mouth.[1]
Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.[2]
Meloxicam/rizatriptan isindicated for the acute treatment of migraine with or without aura in adults.[1][3]
Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.[2]
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key:underline indicates initially developed first-in-class compound of specific group;#WHO-Essential Medicines;†withdrawn drugs;‡veterinary use. | |
